UTHSCSA - Faculty Profiles

Search All | Profile | Publications | Grants | Faculty Index

DeFronzo, M.D., Ralph A

School of Medicine
Medicine
(210) 567-6691
albarado@uthscsa.edu

My major interests focus on the pathogenesis and treatment of type 2 diabetes mellitus, the central role of insulin resistance in the metabolic-cardiovascular cluster of disorders-known collectively as the Insulin Resistance Syndrome, and the etiology and treatment of diabetic nephropathy. Using the euglycemic insulin clamp technique in combination with radioisotope turnover methodology, limb catheterization, indirect calorimetry, and muscle biopsy, I have helped to define the biochemical and molecular disturbances responsible for insulin resistance in type 2 diabetes mellitus.

Appointments Education Expertise Publications Grants

12/1994 - Present	Deputy Director	Texas Diabetes Institute, San Antonio, TX
12/1988 - Present	Staff Physician	South Texas Veterans Health Care System - Audie L. Murphy Division, San Antonio, TX
9/1988 - Present	Professor of Medicine	UTHSCSA, Medicine/Diabetes, San Antonio, TX
9/1988 - Present	Division Chief, Diabetes	UTHSCSA, Medicine/Diabetes, San Antonio, TX
9/1988 - Present	Director, Diabetes Research Unit	Diabetes Research Unit, Barrter Research Unit, UTHSCSA, San Antonio, TX

Journal Article

Abdul-Ghani MA, Norton L, DeFronzo RA. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia Diabetes Obes Metab 2012 Jun;12(3):230-238.

Armato J, DeFronzo RA, Abdul-Ghani M, Ruby R. Successful treatment of Prediabetes in Clinical Practice: Targeting Insulin Resistance and B-Cell Dysfunction Endocr Pract 2012 May;18(3):342-350.

Abdul-Ghani MA, Williams K, Kanat M, Altuntas Y, Defronzo RA, DeFronzo, M.D. RA. Insulin Versus GLP-1 Analogues in Poorly Controlled Type 2 Diabetic Subjects on Oral Therapy A Meta Analysis J Endocrinol Invest 2012 Apr;.

Jensen J, Tantiwong P, Stuenaes JT, Molina-Carrion M, DeFronzo RA, Sakamoto K, Musi N. Effect of acute exercise on glycogen synthase in muscle from obese and diabetic subjects Am J Physiol Endocrinol Metab 2012 Apr;.

DeFronzo RA, Burant CF, Fleck P, Wilson C, Mekki Q, Pratley RE. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes J Clin Endocrinol Metab 2012 Mar;97(5):1615-1622.

Doiron B, Hu W, Norton L, DeFronzo RA. Lentivirus shRNA Grb10 targeting the pancreas induces apoptosis and improved glucose tolerance due to decreased palsma glucagon levels Diabetologia 2012 Mar;55(3):719-728.

Kanat M, Mari A, Norton L, Winnier D, DeFronzo RA, Jenkinson C, Abdul-Ghani MA. Distinct b-cell defects in impaired fasting glucose and impaired glucose tolerance Diabetes 2012 Feb;61(2):447-453.

Doiron B Hu W Norton L DeFronzo RA. Lentivirus shRNA Grb10 Targeting The Pancreas Induces Apoptosis And Improved Glucose Tolerance due to Decreased Plasma Glucagon Levels Diabetologia 2012 Jan;55:719-728.

Anderwald C, Gastaldelli A, Tura A, Krebs M, Promintzer-Schifferl M, Kautzky-Willer A, Stadler M, DeFronzo RA, Pacini G, Bischoff MG. Mechanism and effects of glucose absorption during an oral glucose tolerance test among females and males J Clin Endocrinol Metab 2011 Oct;:515-524.

Kanat M, Norton L, Winnier D, Jenkinson C, Defronzo RA, Abdul-Ghani MA, DeFronzo, M.D. RA. Impaired early- but not late-phase insulin secretion in subjects with impaired fasting glucose Acta Diabetol 2011 Sep;48(3):209-217.

Abdul-Ghani MA, Abdul-Ghani T, Stern MP, Karavic J, Tuomi T, Bo I, Defronzo RA, Groop L, DeFronzo, M.D. RA. Two-Step Approach for the Prediction of Future Type 2 Diabetes Risk Diabetes Care 2011 Sep;34(9):2108-2112.

Deepa SS, Zhou L, Ryu J, Wang C, Mao X, Li C, Zhang N, Musi N, Defronzo RA, Liu F, Dong LQ, DeFronzo, M.D. RA. APPL1 Mediates Adiponectin-Induced LKB1 Cytosolic Localization Through the PP2A-PKC{zeta} Signaling Pathway Mol Endocrinol 2011 Aug;.

Abdul-Ghani MA, Norton L, DeFronzo RA, DeFronzo, M.D. RA. Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes Endocr Rev 2011 Aug;32(4):515-531.

DeFronzo RA, Abdul-Ghani M, DeFronzo, M.D. RA. Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose Am J Cardiol 2011 Aug;108(3 Sup):3-24.

Ferrannini E, Betteridge DJ, Dormandy JA, Charbonnel B, Wilcox RG, Spanheimer R, Erdmann E, DeFronzo RA, Laakso M, DeFronzo, M.D. RA. High-density lipoprotein-cholesterol and not HbA1c was directly related to cardiovascular outcome in PROactive Diabetes Obes Metab 2011 Aug;13(8):759-764.

DeFronzo RA, Abdul-Ghani MA, DeFronzo, M.D. RA. Preservation of {beta}-Cell Function: The Key to Diabetes Prevention J Clin Endocrinol Metab 2011 Aug;96(8):2354-2366.

Abdul-Ghani MA, Abdul-Ghani T, Mller G, Bergmann A, Fischer S, Bornstein S, Defronzo RA, Schwarz P, DeFronzo, M.D. RA. Role of Glycated Hemoglobin in the Prediction of Future Risk of T2DM J Clin Endocrinol Metab 2011 Aug;96(8):2596-2600.

DeFronzo RA, Abdul-Ghani M, DeFronzo, M.D. RA. Type 2 diabetes can be prevented with early pharmacological intervention Diabetes Care 2011 May;34 Su:202-209.

Kanat M, Winnier D, Norton L, Arar N, Jenkinson C, Defronzo RA, Abdul-Ghani MA. The relationship between {beta}-cell function and glycated hemoglobin: results from the veterans administration genetic epidemiology study Diabetes Care 2011 Apr;34(4):1006-1010.

Puppala S, Coletta DK, Schneider J, Hu SL, Farook VS, Dyer TD, Arya R, Blangero J, Duggirala R, DeFronzo RA, Jenkinson CP. Genome-wide linkage screen for systolic blood pressure in the Veterans Administration Genetic Epidemiology Study (VAGES) of Mexican Americans and confirmation of a major susceptibility locus on chromosome 6q14.1 Human Heredity 2011 Feb;71(1):1-10.

Kashyap SR, Roman LJ, Masters BS, Mandarino L, DeFronzo R, Bajaj M. Hypoadiponectinemia is closely associated with impaired nitric oxide synthase activity in skeletal muscle of type 2 diabetic subjects Metabol Synd Related Disorders 2010 Oct;8(5):459-463.

Triplitt C, Cersosimo E, DeFronzo RA. Pioglitazone and alogliptin combination therapy in type 2 diabetes: A pathophysiologically sound treatment Vasc Health Risk Management 2010 Sep;7(6):671-690.

Glass LC, Cusi K, Berria R, Petz R, Cersosimo E, DeFronzo RA, Gastaldelli A. Pioglitazone improvement of fasting and postprandial hyperglycaemia in Mexican-American patients with Type 2 diabetes: a double tracer OGTT study Clin Endocrinol (Oxf) 2010 Sep;73(3):339-345.

Bloomgarden ZT, Drexler A, DeFronzo RA, Lebovitz HE, Peters A, Roberts VL, Palumbo P, Weir MR, Levy P, Hennessey JV, Klein I, Brett EM, Kendall DM, Chilton R, Einhorn D, Kaplan LM, Pinkney J, Ismail-Beigi F, Hirsch IB, Raskin P. Summaries of Symposia Confucted in Conjunction with the 19th Annual Meeting and Clinical Congress of the American Association of Clinical Endocrinologists Endocr Pract 2010 Sep;1(16):1-49.

Triplitt C, Cersosimo E, DeFronzo RA, DeFronzo, M.D. RA. Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment Vasc Health Risk Manag 2010 Sep;6:671-690.

Schernthaner G, Barnett AH, Betteridge DJ, Carmena R, Ceriello A, Charbonnel B, Hanefeld M, Lehmann R, Malecki MT, Nesto R, Pirags V, Scheen A, Seufert J, Sjoholm A, Tsatsoulis A, DeFronzo R. Is the ADA/EASD algorithm for the management of type 2 diabetes based on evidence or opinion? A critical analysis Diabetologia 2010 Jul;53(7):1258-1269.

Gastaldelli A, Folli F, DeFronzo RA. The product of triglycerides and glucose as index of insulin resistance. Validation in the SAM study J Clin Endo Metab 2010 Jul;95(7):3347-3351.

DeFronzo RA, Matsuda M, DeFronzo, M.D. RA. Reduced time points to calculate the composite index Diabetes Care 2010 Jul;33(7):93-93.

DeFronzo RA, Matsuda M. Reduced time points to calculate the compositive index Diabetes Care 2010 Jun;33(7).

Blanco CL, Hanyu L, Joya-Galeana J, DeFronzo M, McCumin D, Musi N. The ontogeny of insulin signaling in the preterm baboon model Endocrinology 2010 May;151(5):1990-1997.

Abdul-Ghani MA, Lyssenko V, Tuomi T, DeFronzo RA, Groop L, Abdul-Ghani M. The shape of plasma glucose concentration curve during OGTT predicts future risk of type 2 diabetes Diabetes Metab Res Rev 2010 May;26(4):280-286.

DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009 Diabetologia 2010 Apr;.

Bajaj M, Baig R, Suraamornkul S, Hardies LJ, Coletta D, Cline GW, Monroy A, Musi N, Shulman GI, DeFronzo RA. Effect of pioglitazone on intramocellular fat metabolism in patients with type 2 diabetes mellitus J Clin Endo Metab 2010 Apr;95(4):1916-1923.

DeFronzo RA. Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going Am J Med 2010 Mar;123(3 Sup):38-48.

Abdul-Ghani MA, Stern MP, Lyssenko V, Tuomi T, Groop L, DeFronzo RA. Minimal contribution of fasting hyperglycemia to the incidence of type 2 diabetes in subjects with normal 2-h plasma glucose Diabetes Care 2010 Mar;33(3):557-561.

DeFronzo RA. Current issues in the treatment of type 2 diabetes. Introduction Am J Med 2010 Mar;123(3 Sup):1-2.

DeFronzo RA, Stonehouse AH, Han J, Wintle ME, DeFronzo, M.D. RA. Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials Diabet Med 2010 Mar;27(3):309-317.

Charbonnel B, DeFronzo R, Davidson J, Schmitz O, Birkeland K, Pirags V, Scheen A; PROactive investigators. Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19) J Clin Endorinol Metab 2010 Mar;95(5):2163-2171.

DeFronzo RA, Banerji MA, Bray GA, Buchanan TA, Clement S, Henry RR, Kitabchi AE, Mudaliar S, Musi N, Ratner R, Reaven P, Schwenke DC, Stentz FD, Tripathy D. Determinants of glucose tolerance in impaired glucose tolerance at baseline in the Actos Now for Prevention of Diabetes (ACT NOW) study Diabetologia 2010 Mar;53(3):435-445.

DeFronzo RA, Stonehouse AH, Han J, Wintle ME. Relationship of baseline HbA1c and efficacy of current antidiabetic therapies: a meta-analysis of randomized clinical trials Diabetic Med 2010 Mar;27(3):309-317.

DeFronzo RA, Triplitt C, Qu Y, Lewis MS, Maggs D, Glass LC. Effects of exenatide plus rosiglitazone on beta bell function and insulin sensitivity in subjects with Type 2 Diabetes on metformin Diabetes Care 2010 Jan;.

Chavez AO, Kamath S, Jani R, Sharma LK, Monroy A, Abdul-Ghani MA, Centonze VE, Sathyanarayana P, Coletta D, Jenkinson C, Bai Y, Folli F, DeFronzo R, Tripathy D. Effect of short-term free fatty acids elevation on mitochondrial function in skeletal muscle of healthy individuals J Clin Endocrinol Metab 2010 Jan;95(1):422-429.

Parhofer KG, Birkeland K, DeFronzo R, Del Prato S, Donovan M, Ptaszynska A. Irbesartan has no short-term effect on insulin resistance in hypertensive patients with additional cardiometabolic risk factors (I-RESPOND) Int J Clin Practice 2010 Jan;64:160-168.

Abdul-Ghani MA, Stern MP, Lyssenko V, Tuomi T, Groop L, DeFronzo RA. Minimal Contribution of Fasting Hyperglycemia to the Incidence of T2DM in Subjects With Normal 2 Hour Plasma Glucose Diabetes Care 2009 Dec;.

DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes Diabetes Care 2009 Nov;32 Su:157-163.

Abdul-Ghani MA, DeFronzo RA. Plasma glucose concentration and prediction of future risk of type 2 diabetes Diabetes Care 2009 Nov;32 Su:194-198.

DeFronzo RA, Hissa MN, Garber AJ, Luiz Gross J, Yuyan Duan R, Ravichandran S, Chen RS. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone Diabetes Care 2009 Sep;32(9):1649-1655.

Miyazaki Y, DeFronzo RA. Visceral fat dominant distribution in male type 2 diabetic patients is closely related to hepatic insulin resistance, irrespective of body type Cardiovasc Diabetol 2009 Aug;8:44-44.

DeFronzo RA, Abdul-Ghani MA. Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels: response to Utzschneider et al Diabetes Care 2009 Jul;32(7):86-86.

DeFronzo RA, Banerji M, Bray GA, Buchanan TA, Clement S, Henry RR, Kitabchi AE, Mudaliar S, Musi N, Ratner R, Reaven PD, Schwenke D, Stentz FB, Tripathy D. Actos NOW for the prevention of diabetes (ACT NOW) study BMC Endocr Disord 2009 Jul;9:17-25.

Abdul-Ghani MA, DeFronzo RA. Pathophysiology of prediabetes Curr Diab Rep 2009 Jun;9(3):193-199.

Chavez A, Molina-Carrion M, Abdul-Ghani M, Folli F, DeFronzo R, Tripathy D. Circulating fibroblast growth factor-21 (FGF-21) is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance Diabetes Care 2009 Jun;32:1542-1546.

Liang H, Balas B, Tantiwong P, Dube JJ, Goodpaster BH, ODoherty RM, DeFronzo RA, Richardson A, Musi N, Ward, WF. Whole-Body Overexpression of PGC-1{alpha} Has Opposite Effects on Hepatic and Muscle Insulin Sensitivity Am J Physiol Endocrinol Metab 2009 Apr;296:E945-E954.

Chavez AO, Gastaldelli A, Guardado-Mendoza R, Lopez-Alvarenga JC, Leland MM, Tejero ME, Sorice G, Casiraghi F, Davalli A, Bastarrachea RA, Comuzzie AG, DeFronzo RA, Folli F. Predictive models of insulin resistance derived from simple morphometric and biochemical indices related to obesity and the metabolic syndrome in baboons Cardiovasc Diabetol 2009 Apr;8:22-22.

Coletta DK, Sriwijitkamol A, Wajcberg E, Tantiwong P, Li M, Prentki M, Madiraju M, Jenkinson CP, Cersosimo E, Musi N, DeFronzo RA. Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial Diabetologia 2009 Apr;52(4):723-732.

DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus Diabetes 2009 Apr;58(4):773-795.

Chavez AO, Coletta DK, Kamath S, Cromack DT, Monroy A, Folli F, DeFronzo RA, Tripathy D. Retinol-binding protein 4 is associated with impaired glucose tolerance but not with whole body or hepatic insulin resistance in Mexican Americans Am J Physiol Endocrinol Metab 2009 Apr;296(4):758-764.

Haus JM, Kashyap SR, Kasumov T, Zhang R, Kelly KR, DeFronzo RA, Kirwan JP. Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance Diabetes 2009 Feb;58(2):337-343.

Abdul-Ghani MA, Lyssenko V, Tuomi T, DeFronzo RA, Groop L. Fasting versus postload plasma glucose concentration and the risk for future type 2 diabetes: results from the Botnia Study Diabetes Care 2009 Feb;32(2):281-286.

Coletta DK, Schneider J, Hu SL, Dyer TD, Puppala S, Farook VS, Arya R, Lehman DM, Blangero J, DeFronzo RA, Duggirala R, Jenkinson CP. Genome-wide linkage scan for genes influencing plasma triglyceride levels in the Veterans Administration Genetic Epidemiology Study Diabetes 2009 Jan;58(1):279-284.

Monroy A, Kamath S, Chavez AO, Centonze VE, Veerasamy M, Barrentine A, Wewer JJ, Coletta DK, Jenkinson C, Jhingan RM, Smokler D, Reyna S, Musi N, Khokka R, Federici M, Tripathy D, DeFronzo RA, Folli F. Impaired regulation of the TNF-alpha converting enzyme/tissue inhibitor of metalloproteinase 3 proteolytic system in skeletal muscle of obese type 2 diabetic patients: a new mechanism of insulin resistance in humans Diabetologia 2009 Jan;52(10):2169-2181.

Gastaldelli A, Perego L, Paganelli M, Sesti G, Hribal M, Chavez AO, DeFronzo RA, Pontiroli A, Folli F. Elevated concentrations of liver enzymes and ferritin identify a new phenotype of insulin resistance: effect of weight loss after gastric banding Obes Surg 2009 Jan;19(1):80-86.

DeFronzo RA, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study Diabetes Care 2008 Dec;31(12):2315-2317.

Miyazaki Y, DeFronzo RA. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients Diabetes Obes Metab 2008 Dec;10(12):1204-1211.

Abdul-Ghani MA, Matsuda M, DeFronzo RA. Strong association between insulin resistance in liver and skeletal muscle in non-diabetic subjects Diabet Med 2008 Nov;25(11):1289-1294.

Rosenstock J, Bergenstal R, DeFronzo RA, Hirsch IB, Klonoff D, Boss AH, Kramer D, Petrucci R, Yu W, Levy B. Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naive type 2 diabetes suboptimally controlled with oral agents Diabetes Care 2008 Nov;31(11):2177-2182.

DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study Curr Med Res Opin 2008 Oct;24(10):2943-2952.

Reyna SM, Ghosh S, Tantiwong P, Meka CS, Eagan P, Jenkinson CP, Cersosimo E, DeFronzo RA, Coletta DK, Sriwijitkamol A, Musi N. Elevated toll-like receptor 4 expression and signaling in muscle from insulin-resistant subjects Diabetes 2008 Oct;57(10):2595-2602.

Abdul-Ghani MA, Abdul-Ghani T, Ali N, DeFronzo RA,. One-hour plasma glucose concentration and the metabolic syndrome identify subjects at high risk for future type 2 diabetes Diabetes Care 2008 Aug;31(8):1650-1655.

Miyazaki Y, Akasaka H, Ohnishi H, Saitoh S, DeFronzo RA, Shimamoto K. Differences in insulin action and secretion, plasma lipids and blood pressure levels between impaired fasting glucose and impaired glucose tolerance in Japanese subjects Hypertens Res 2008 Jul;31(7):1357-1363.

Jenkinson CP, Coletta DK, Flechtner-Mors M, Hu SL, Fourcaudot MJ, Rodriguez LM, Schneider J, Arya R, Stern MP, Blangero J, Duggirala R, DeFronzo RA. Association of genetic variation in ENPP1 with obesity-related phenotypes Obesity (Silver Spring) 2008 Jul;16(7):1708-1713.

Abdul-Ghani MA, Masafumi M, Jani R, Jenkinson CP, Richardson DK, Kaku K, DeFronzo RA. The relationship between fasting hyperglycemia and insulin secretion in subjects with normal or impaired glucose tolerance Am J Physiol Endo Metab 2008 May;295(2):E401-E406.

Coletta DK, Balas B, Chavez AO, Baig MR, Abdul-Ghani M, Kashyap SR, Folli F, Tripathy D, Mandarino LJ, Cornell JE, DeFronzo M, Jenkinson CP. Effect of acute physiological hyperinsulinemia on gene expression in human skeletal muscle in vivo Am J Physiol Endocrinol Metab 2008 May;294(5):E910-917.

Chavez AO, Lopez-Alvarenga JC, Tejero ME, Triplitt C, Bastarrachea RA, Sriwijitkamol A, Tantiwong P, Voruganti VS, Musi N, Comuzzie AG, DeFronzo RA, Folli F. Physiological and molecular determinants of insulin action in the baboon Diabetes 2008 Apr;57(4):899-908.

Betteridge DJ, DeFronzo RA, Chilton RJ. PROactive: time for a critical appraisal Eur Heart J 2008 Apr;29(8):969-983.

Cervera A, Wajcberg E, Sriwijitkamol A, Fernandez M, Zuo P, Triplitt C, Musi N, DeFronzo RA, Cersosimo E. Mechanism of Action of Exenatide to Reduce Postprandial Hyperglycemia In Type 2 Diabetes Am J Physiol Endocrinol Metab 2008 Mar;.

Abdul-Ghani MUHAMMAD, Molina-Carrion M, Jani R, Jenkinson C, DeFronzo RA, Jenkinson CP. Adipocytes in subjects with impaired fasting glucose and impaired glucose tolerance are resistant to the anti-lipolytic effect of insulin Acta Diabetol 2008 Mar;.

Thomaseth K, Pavan A, Berria R, Glass L, DeFronzo R, Gastaldelli A, DeFronzo RA. Model-based assessment of insulin sensitivity of glucose disposal and endogenous glucose production from double-tracer oral glucose tolerance test Comput Methods Programs Biomed 2008 Feb;89(2):132-140.

Jani R, Molina M, Matsuda M, Balas B, Chavez A, DeFronzo RA, Abdul-Ghani M. Decreased non-insulin-dependent glucose clearance contributes to the rise in fasting plasma glucose in the nondiabetic range Diabetes Care 2008 Feb;31(2):311-315.

Kashyap SR, Lara A, Zhang R, Park YM, DeFronzo RA. Insulin reduces plasma arginase activity in type 2 diabetic patients Diabetes Care 2008 Jan;31(1):134-139.

Schneider CA, Ferrannini E, Defronzo R, Schernthaner G, Yates J, Erdmann E, DeFronzo RA. Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease J Am Soc Nephrol 2008 Jan;19(1):182-187.

Miyazaki Y, Cersosimo E, Triplitt C, DeFronzo RA. Rosiglitazone decreases albuminuria in type 2 diabetic patients Kidney Int 2007 Sep;.

Wang L, Balas B, Christ-Roberts CY, Kim RY, Ramos FJ, Kikani CK, Li C, Deng C, Reyna S, Musi N, Dong LQ, DeFronzo RA, Liu F. Peripheral disruption of the Grb10 gene enhances insulin signaling and sensitivity in vivo Mol Cell Biol 2007 Sep;27:6497-6505.

Gastaldelli A, Cusi K, Pettiti M, Hardies J, Miyazaki Y, Berria R, Buzzigoli E, Sironi AM, Cersosimo E, Ferrannini E, DeFronzo RA. Relationship between hepatic insulin resistance in nondiabetic and type 2 diabetic subjects Gastroenterology 2007 Aug;133(2):496-506.

Gastaldelli A, Cusi K, Petitti M, Hardies LJ, Miyazaki Y, Berria R, Buzzigoli E, Sironi AM, Cersosimo E, Ferrannini E, DeFronzo RA. Relationship between visceral/hepatic fat content and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects Gastroenterology 2007 Aug;133(2):496-506.

Abdul-Ghani MA, Williams K, DeFronzo RA, Stern M. What is the best predictor of future type 2 diabetes? Diabetes Care 2007 Jun;30(6):1544-1548.

Abdul-Ghani MA, Matsuda M, Sabbah M, Jenkinson C, Richardson DK, DeFronzo RA. The relative contribution of insulin resistance and beta cell failure to the transition from normal to impaired glucose tolerance varies in different ethnic groups Diab Metab Synd 2007 Jun;1(2):105-112.

Review Article

Pozzilli P, Leslie RD, Chan J, DeFronzo R, Monnier L, Raz I, Del Prato S. The A1C and ABCD of type 2 diabetes management Diabetes/Metab Research Rev 2010 May;26(4):239-244.

Abdul-Ghani MA, DeFronzo RA,. Pathogenesis of insulin resistance in skeletal muscle J Biomed Biotechnol 2010 Apr;2010:476279-476279.

Abdul-Ghani MA, DeFronzo RA,. Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus Endocr Pract 2008 Sep;14(6):782-790.

Abdul-Ghani MA, DeFronzo RA,. Mitochondrial dysfunction, insulin resistance, and type 2 diabetes mellitus Curr Diab Rep 2008 Jun;8(3):173-178.

Editorial

DeFronzo RA, DeFronzo, M.D. RA. Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes Diabetes Care 2011 Apr;34(4):789-794.

Federal
Funding Agency	Eli Lilly & Company
Title	Durability of early initial combination therapy with exenatide/pioglitazone/metformin vs conventional therapy in new onset type 2 diabetes
Status	Active
Period	1/2009 - Present
Role	Co-Investigator
Grant Detail
Funding Agency	Novartis Pharmaceuticals Corp
Title	The role of inflammatory, insulin signaling, and adipocytokine mechanisms in the prevention of type 2 diabetes mellitus in subjects treated with diovan
Status	Active
Period	1/2008 - Present
Role	Co-Investigator
Grant Detail
Funding Agency	NIH/NIDDK
Title	Heterogeneity, Glycemic Control & Macro-Vascular Complications in Type 2 Diabetes
Status	Complete
Period	6/2006 - 1/2012
Role	Contributor
Grant Detail	To support an integrated program of training and research to develop an independent research career in statistical methods pertinent to the design and testing of interventions aimed at reducing diabetes-related cardiovascular disease for patients with type 2 diabetes.
Funding Agency
Title	Takeda Pharmaceuticals North America (2003-2011) Actos Now for Prevention of Diabetes (ACT NOW)
Status	Active
Period	1/2003 - 1/2011
Role	Co-Investigator
Grant Detail
Funding Agency	VA
Title	Veterans Administration Research Service - Molecular Epidemiology of Type 2 Diabetes Mellitus in Mexican Americans
Status	Active
Period	10/2005 - 9/2010
Role	Principal Investigator
Grant Detail
Private
Funding Agency	American Diabetes Association
Title	American Diabetes Association - Mentor-Based Minority Postdoctoral Fellowship Award
Status	Active
Period	7/2008 - 6/2011
Role	Principal Investigator
Grant Detail
Funding Agency	American Diabetes Association
Title	Durability of early combination therapy vs conventinal therapy in new onset diabetes
Status	Active
Period	7/2008 - 6/2011
Role	Principal Investigator
Grant Detail

Year	Degree	Discipline	Institution
1975	Postdoctoral Fellowship	Renal	Hospital of the University of Pennsylvania Philadelphia , PA
1973	Postdoctoral Fellowship	Endocrinology	Gerontology Research Center, NIMHCD and Baltimore City Hospital Baltimore , MD
1971	Internship		Johns Hopkins Hospital Baltimore , MD
1970	Internship		Johns Hopkins Hopsital Baltimore , MD
1969	MD	Medicine (Cum Laude)	Harvard Medical School Boston , MA
1969	MS	Medicine (Cum Laude)	Boston College Graduate School of Biology Chestnut Hill , MA
1967	BMS	Medicine	Dartmouth Medical School Hanover , NH
1964	BS	Biology/Biochemistry	Yale Univeristy New Haven , CT

Faculty

FAQ

Suggestions

DeFronzo, M.D., Ralph A

Diabetes

Journal Article

Review Article

Editorial

Federal

Private